TSW
FENC icon

Thompson Siegel & Walmsley’s Fennec Pharmaceuticals FENC Stock Holding History

Thompson Siegel & Walmsley’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$615K Hold
57,226
– – 0.01% 350
2026
Q1 		$352K Buy
+57,226
New +$442K 0.01% 384

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Thompson Siegel & Walmsley's FENC Position: Q2 2026 in Review

Thompson Siegel & Walmsley held its Fennec Pharmaceuticals (FENC) position steady in Q2 2026 at 57,226 shares worth $615K. The position accounts for 0.01% of the portfolio, ranked #350.

Thompson Siegel & Walmsley first reported a position in FENC in Q1 2026 and has held it in 2 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Thompson Siegel & Walmsley held 57,226 shares of Fennec Pharmaceuticals worth $615K as of Q2 2026.
  • Thompson Siegel & Walmsley left its Fennec Pharmaceuticals share count unchanged in Q2 2026.
  • Fennec Pharmaceuticals made up 0.01% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #350 holding.
  • Thompson Siegel & Walmsley first reported a position in Fennec Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.